Together, these results demonstrate that the absence of CD4+ T cells reduces liver injury, inflammation, and fibrosis in the context of FFC-induced MASH, without impacting systemic metabolic dysfunction. The gene discussed is CD4; the disease is metabolic dysfunction-associated steatohepatitis.